<SUBMISSION>
<SECRELEASE-DATETIME> 20170124-163132 ⇐ Metadata from SEC Info (ET)
<SECWEBSITE-DATETIME> 20170124-163132 ⇐ Metadata from SEC Info (ET)
<ACCEPTANCE-DATETIME> 20170124-163043 ⇐ Filing accepted by SEC (ET)
<ACCESSION-NUMBER> 0001437749-17-001041
<TYPE> S-8
<PUBLIC-DOCUMENT-COUNT> 4
<REFERENCES-429> 333-147334
<REFERENCES-429> 333-157041
<REFERENCES-429> 333-164469
<REFERENCES-429> 333-171981
<REFERENCES-429> 333-180461
<REFERENCES-429> 333-185998
<REFERENCES-429> 333-194383
<REFERENCES-429> 333-196764
<REFERENCES-429> 333-203109
<REFERENCES-429> 333-208985
<REFERENCES-429> 333-211754
<FILING-DATE> 20170124
<DATE-OF-FILING-DATE-CHANGE> 20170124
<EFFECTIVENESS-DATE> 20170124
|
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME> NovaBay Pharmaceuticals, Inc.
<CIK> 0001389545
<ASSIGNED-SIC> 2834
<IRS-NUMBER> 680454536 ⇒ 68-0454536
<STATE-OF-INCORPORATION> DE
<FISCAL-YEAR-END> 1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE> S-8
<ACT> 33
<FILE-NUMBER> 333-215680
<FILM-NUMBER> 17544062
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1> 2000 POWELL STREET, SUITE 1150
<CITY> EMERYVILLE
<STATE> CA
<ZIP> 94608
<PHONE> (510) 899-8800
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1> 2000 POWELL STREET, SUITE 1150
<CITY> EMERYVILLE
<STATE> CA
<ZIP> 94608
</MAIL-ADDRESS>
</FILER>
|
<DOCUMENT>
<TYPE> S-8
<SEQUENCE> 1
<FILENAME> nby20170109_s8.htm
<DESCRIPTION> FORM S-8
<TEXT>
<HTML>
Show <HTML>: 834 lines (widest: 1,918 characters) - 91K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> EX-5.1
<SEQUENCE> 2
<FILENAME> ex5-1.htm
<DESCRIPTION> EXHIBIT 5.1
<TEXT>
<HTML>
Show <HTML>: 91 lines (widest: 1,432 characters) - 13K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> EX-23.1
<SEQUENCE> 3
<FILENAME> ex23-1.htm
<DESCRIPTION> EXHIBIT 23.1
<TEXT>
<HTML>
Show <HTML>: 17 lines (widest: 1,085 characters) - 4K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> EX-99.1
<SEQUENCE> 4
<FILENAME> ex99-1.htm
<DESCRIPTION> EXHIBIT 99.1
<TEXT>
<HTML>
Show <HTML>: 314 lines (widest: 2,442 characters) - 100K bytes
</TEXT>
</DOCUMENT>
|
</SUBMISSION> |
| ↑Top |
